Using nicotine replacement therapy to assist in reducing cigarette consumption before quitting: Another strategy for smoking cessation?

Disease Management and Health Outcomes

Volumn 14, Issue 6, 2006, Pages 335-340

  McRobbie, Hayden ^a   Whittaker, Robyn ^a   Bullen, Christopher ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; PLACEBO; VARENICLINE;

BEHAVIOR THERAPY; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HEART PALPITATION; HICCUP; HUMAN; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT ATTITUDE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TREATMENT INDICATION; WITHDRAWAL SYNDROME;

EID: 33846346675     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200614060-00003     Document Type: Review

References (48)

1. Mackay J, Eriksen M. The tobacco atlas: World Health Organization 2002 [online]. Available from URL: http://www.who.int/tobacco/statistics/ tobacco_atlas/en/ [Accessed 2006 July 3]
2. Balfour DJ. Neural mechanisms underlying nicotine dependence. Addiction 1994; 89 (11): 1419-23
3. Balfour D. The neurobiology of tobacco dependence: a preclinical perspective on the role of dopamine projections to the nucleus. Nicotine Tob Res 2004; 6 (6): 899-912
4. Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 1992; 60 (5): 689-97
5. Hajek P, Gillison F, McRobbie H. Stopping smoking can cause constipation. Addiction 2003; 98 (11): 1563-7
6. McRobbie H, Hajek P, Gillison F. The relationship between smoking cessation and mouth ulcers. Nicotine Tob Res 2004; 6 (4): 655-9
7. Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 1997; 5 (2): 137-42
8. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29 (7): 1422-31
9. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328 (7455): 1519
10. West R, Shiffman S. Fast facts: smoking cessation. Oxford: Health Press Ltd, 2004
11. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99 (1): 29-38
12. Royal College of Physicians. Nicotine addiction in Britain. London: Royal College of Physicians, 2000
13. Sutherland G. Evidence for counseling effectiveness for smoking cessation. J Clin Psychiatry Monograph 2003; 18 (1): 22-34
14. US Department of Health and Human Services. Treating tobacco use and dependence. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research Quality, 2000
15. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004 (3): CD000146
16. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004 (4): CD000031.pub2
17. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55 (12): 987-99
18. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1): 47-55
19. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1): 56-63
20. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166 (15): 1561-8
21. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166 (15): 1571-7
22. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1): 64-71
23. Center for Drug Evaluation and Research, US Food and Drug Administration. Drugs@FDA: FDA approved drug products. Drug details: Chantix, NDA no. 021928 2006 [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Accessed 2006 Oct 2]
24. Benowitz N, Prochet H, Jacob PR. Pharmacokinetics, metabolism and pharmacodynamics of nicotine. In: Wonnacott S, Russell MAH, Stolerman IP, editors. Nicotine psychopharmacology: molecular, cellular, and behavioural aspects. Oxford: Oxford University Press, 199-0
25. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 2001 Nov; 96 (11): 1547-51
26. Benowitz N, Dempsey D. Pharmacotherapy for smoking cessation during pregnancy. Nicotine Tob Res 2004; 6 Suppl. 2: S189-202
27. Shiffman S, Gitchell J, Pinney JM, et al. Public health benefit of over-the-counter nicotine medications. Tob Control 1997; 6 (4): 306-10
28. Pfizer. Nicorette® reduce to stop [promotional material]. Pfizer, 2006
29. Pfizer. Reducing to stop with NRT: a new route to smoking cessation. Pfizer, 2006
30. McEwen A, West R. Smoking cessation activities by general practitioners and practice nurses. Tob Control 2001; 10 (1): 27-32
31. West R, McEwen A, Bolling K, et al. Smoking cessation and smoking patterns in the general population: a 1-year follow-up. Addiction 2001; 96 (6): 891-902
32. Hughes JR. Reduced smoking: an introduction and review of the evidence. Addiction 2000; 95 Suppl. 1: S3-7
33. Benowitz NL. The use of biologic fluid samples in assessing tobacco smoke consumption. NIDA Res Monogr 1983; 48: 6-26
34. Kozlowski LT, Mehta NY, Sweeney CT, et al. Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States. Tob Control 1998; 7 (4): 369-75
35. Cinciripini PM, Lapitsky L, Seay S, et al. The effects of smoking schedules on cessation outcome: can we improve on common methods of gradual and abrupt nicotine withdrawal? J Consult Clin Psychol 1995; 63 (3): 388-99
36. Carpenter MJ, Hughes JR, Solomon LJ, et al. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol 2004; 72 (3): 371-81
37. Medicines and Healthcare products Regulatory Agency. Report of the Committee on Safety of Medicines Working Group on nicotine replacement therapy: MHRA, Committee on Safety of Medicines, 2005 [online]. Available from URL: http://www.mhra.gov.uk/home/idcplg?.IdcService=GET_FILE&d-DocName= CON2023239&RevisionSelectionMethod=LatestReleased [Accessed 2006 Jul 3]
38. Fagerstrom KO, Tejding R, Westin A, et al. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tob Control 1997; 6 (4): 311-6
39. Wennike P, Danielsson T, Landfeldt B, et al. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 2003; 98 (10): 1395-402
40. Bolliger CT, Zellweger JP, Danielsson T, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ 2000; 321 (7257): 329-33
41. Batra A, Klingler K, Landfeldt B, et al. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther 2005; 78 (6): 689-96
42. Etter JF, Laszlo E, Zellweger JP, et al. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol 2002; 22 (5): 487-95
43. Rennard SI, Glover ED, Leischow S, et al. Efficacy of the nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine Tob Res 2006; 8 (4): 555-64
44. Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update. Addiction 2005; 100 (8): 1074-89
45. Action on Smoking and Health. Nicotine assisted reduction to stop (NARS): guidance for health professionals on this new indication for nicotine replacement therapy. London: Action on Smoking and Health, 2005 [online]. Available from URL: http://www.ash.org.uk/html/cessation/Smoking%20reduction/ NARS051014.pdf [Accessed 2006 Jul 3]
46. Pfizer Limited. Cut down gradually with Nicorette then stop [online]. Available from URL: http://www.cutdowntostop.co.uk [Accessed 2006 Jul 3]
47. Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003; 163 (19): 2337-44
48. Hatsukami DK, Rennard S, Patel MK, et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. Am J Med 2004; 116 (3): 151-7